On November 5, GENSCRIPT B-1K fell 3.24% in Regular Trading, trading at HK$33.18, with turnover of HK$249 million.
The latest disclosed catalyst was an event-driven update: its associate Legend Biotech announced it had filed a Form 6-K and will present CARVYKTI study results for multiple myeloma at the 68th American Society of Hematology annual meeting in New Orleans from December 12 to 15.
The planned disclosures include two oral presentations, two poster presentations and one electronic publication. This follows the company’s recent clarification that its business and operations remain normal and that the earlier talk about a trading counter closure referred only to the temporary counter created during the board lot change from 2,000 shares to 1,000 shares, rather than a full closure.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments